dc.creatorTalevi, Alan
dc.date2015
dc.date2019-11-20T12:21:29Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/85738
dc.identifierissn:1663-9812
dc.descriptionMulti-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
dc.descriptionFacultad de Ciencias Exactas
dc.formatapplication/pdf
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.subjectCiencias Exactas
dc.subjectDesigned multiple ligands
dc.subjectDrug design
dc.subjectDrug repositioning
dc.subjectDrug resistance
dc.subjectGene profile
dc.subjectLock and key paradigm
dc.subjectMulti-target agents
dc.titleMulti-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
dc.typeArticulo
dc.typeArticulo


Este ítem pertenece a la siguiente institución